Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Should adults with autoimmune rheumatic conditions receive updated COVID-19 vaccines? (opens in a new tab)

medicalxpress.com · 2026-09-09

Short answerEvidenceSource

Short answer

Mixed

Mixed.

One claim goes further than the study. One other point was not covered by the paper.

  • 3 supported
  • 1 overstated
  • 1 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

One claim overstates the study. Three of five check out. One claim the study doesn't address.

  • 3 supported
  • 1 overstated
  • 1 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5OverstatedThe corresponding author said the findings provide important real-world evidence that updated vaccines continue to offer substantial protection in this medically vulnerable population.View evidenceHide evidence

As statedsubstantial protection

Why this verdict

The underlying finding supports an association between updated vaccination and lower adjusted odds of hospitalization. However, saying updated vaccines 'continue to offer substantial protection' frames the observational result in stronger protective/causal terms than the retrospective cohort design can establish from abstract-level evidence. The exact corresponding-author quotation is also not verifiable from the supplied paper profile, but the main problem is the causal-strength wording.

1

Study evidence

Receipt of COVID-19 vaccination was associated with lower adjusted odds of COVID-19–related hospitalization compared with no vaccination; adjusted odds ratios were 0.59 (initial series), 0.29 (booster), and 0.31 (updated 2023–2024) versus unvaccinated.initial series aOR 0.59 (95% CI 0.56–0.63); booster aOR 0.29 (95% CI 0.27–0.31); updated aOR 0.31 (95% CI 0.28–0.34)

“We conducted a retrospective cohort study using National Clinical Cohort Collaborative (N3C) data”
Claim 2 of 5Not coveredThe first author said the results underscore the need for continued efforts by clinicians, policymakers and patient advocacy groups to help ensure that these patients remain current with updated COVID-19 vaccines.View evidenceHide evidence

As statedremain current with updated COVID-19 vaccines

Why this verdict

The general implication that updated vaccination should be supported is consistent with the paper profile’s abstract-level discussion, which says the authors recommend support for updated vaccinations in this population. However, the specific first-author attribution and the detailed call for clinicians, policymakers, and patient advocacy groups are not verifiable from the supplied abstract-level profile.

1

Study evidence

Receipt of COVID-19 vaccination was associated with lower adjusted odds of COVID-19–related hospitalization compared with no vaccination; adjusted odds ratios were 0.59 (initial series), 0.29 (booster), and 0.31 (updated 2023–2024) versus unvaccinated.initial series aOR 0.59 (95% CI 0.56–0.63); booster aOR 0.29 (95% CI 0.27–0.31); updated aOR 0.31 (95% CI 0.28–0.34)

“We conducted a retrospective cohort study using National Clinical Cohort Collaborative (N3C) data”
Claim 3 of 5SupportedIn an Arthritis & Rheumatology analysis of data on 60,980 U.S. adults with autoimmune rheumatic conditions who developed COVID-19 between December 2020 and August 2024, those who received booster or updated (2023–2024) COVID-19 vaccines were less likely to be hospitalized for COVID-19 than those who received only the initial vaccine series or were unvaccinated.View evidenceHide evidence

Why this verdict

The abstract-level profile supports the main association: in a retrospective N3C cohort of 60,980 adults with autoimmune rheumatic conditions and incident COVID-19 from Dec 2020–Aug 2024, booster and updated 2023–2024 vaccination were associated with lower adjusted odds of COVID-19-related hospitalization than no vaccination, and the authors conclude booster/updated vaccination was associated with decreased odds relative to initial series alone or no vaccination. The wording is somewhat direct, but the claim is framed as an analysis finding rather than a causal proof.

1

Study evidence

Receipt of COVID-19 vaccination was associated with lower adjusted odds of COVID-19–related hospitalization compared with no vaccination; adjusted odds ratios were 0.59 (initial series), 0.29 (booster), and 0.31 (updated 2023–2024) versus unvaccinated.initial series aOR 0.59 (95% CI 0.56–0.63); booster aOR 0.29 (95% CI 0.27–0.31); updated aOR 0.31 (95% CI 0.28–0.34)

“We conducted a retrospective cohort study using National Clinical Cohort Collaborative (N3C) data”
Claim 4 of 5SupportedCompared with no vaccination, completion of the initial series, booster vaccination and updated vaccination were associated with 41%, 71% and 69% lower adjusted odds of COVID-19-related hospitalization, respectively.View evidenceHide evidence

As stated41%, 71% and 69% lower adjusted odds

Why this verdict

The percentages match the reported adjusted odds ratios versus unvaccinated patients: initial series aOR 0.59 equals 41% lower adjusted odds, booster aOR 0.29 equals 71% lower adjusted odds, and updated 2023–2024 vaccine aOR 0.31 equals 69% lower adjusted odds.

1

Study evidence

Receipt of COVID-19 vaccination was associated with lower adjusted odds of COVID-19–related hospitalization compared with no vaccination; adjusted odds ratios were 0.59 (initial series), 0.29 (booster), and 0.31 (updated 2023–2024) versus unvaccinated.initial series aOR 0.59 (95% CI 0.56–0.63); booster aOR 0.29 (95% CI 0.27–0.31); updated aOR 0.31 (95% CI 0.28–0.34)

“We conducted a retrospective cohort study using National Clinical Cohort Collaborative (N3C) data”
Claim 5 of 5SupportedAmong patients who had received only the initial vaccine series versus a booster or updated vaccine, the absolute risk reduction was 5.6%.View evidenceHide evidence

As stated5.6% absolute risk reduction

Why this verdict

The paper profile explicitly reports that among patients who had received only the initial vaccine series versus a booster or updated vaccine, the absolute risk reduction for COVID-19-related hospitalization was 5.6%. The abstract-level profile does not provide precision or denominator details, but the stated point estimate is supported.

1

Study evidence

Among patients who had received only the initial vaccine series versus a booster/updated vaccine, the absolute risk reduction for COVID‑19–related hospitalization was 5.6% (reported in abstract).5.6% absolute risk reduction

“Among patients who had received only the initial vaccine series versus a booster/updated vaccine, the absolute risk reduction was 5.6%.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Important limitation: the study was retrospective and observational, so adjusted associations do not establish causality and may be affected by residual confounding or selection bias.

    The paper profile flags the retrospective observational design and the caveat that causality is not established. The story presentation lists no caveats and includes at least one protection-oriented quote that could be read causally.

    From Retrospective cohort (EHR-derived, N3C); Retrospective cohort subgroup contrast (initial-series-only vs booster/updated)

  • Important limitation for the absolute risk reduction: the abstract reports the 5.6% point estimate without confidence interval, subgroup denominators, underlying risks, or whether the risk difference was adjusted or unadjusted.

    The story reports the 5.6% ARR but does not mention the uncertainty and derivation limitations noted in the abstract-level profile.

    From Retrospective cohort subgroup contrast (initial-series-only vs booster/updated)

  • Updated-vaccine subgroup size: 6,336 participants, about 10% of the cohort, had received an updated 2023–2024 vaccine.

    The story mentions the overall cohort size but not the relatively smaller updated-vaccine subgroup, which is relevant context for interpreting the updated-vaccine estimate.

    From Retrospective cohort (EHR-derived, N3C)

3 things the story did carry across
  • Primary study design and population: retrospective N3C cohort of 60,980 U.S. adults with autoimmune rheumatic conditions and incident COVID-19 from December 2020 through August 2024.
  • Primary outcome finding: booster and updated 2023–2024 vaccination were associated with lower adjusted odds of COVID-19-related hospitalization compared with unvaccinated patients, and with lower hospitalization risk relative to initial-series-only vaccination.
  • Absolute risk reduction: initial-series-only versus booster/updated vaccination comparison had a reported 5.6% absolute risk reduction for COVID-19-related hospitalization.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataEstimate the association between COVID-19 vaccination status (unvaccinated, initial series, booster, updated 2023–2024 vaccine) and COVID-19–related hospitalization among adults with autoimmune rheumatic conditions with incident COVID-19 (Dec 2020–Aug 2024) using N3C data.Retrospective cohort (EHR-derived, N3C)Expand

In plain English

Retrospective cohort study of 60,980 adults with autoimmune rheumatic conditions and incident COVID-19 (Dec 2020–Aug 2024) using N3C data. Primary outcome was COVID-19–related hospitalization. Compared with unvaccinated patients, adjusted odds of hospitalization were lower for those who received the initial vaccine series (aOR 0.59, 95% CI 0.56–0.63), a booster (aOR 0.29, 95% CI 0.27–0.31), or an updated 2023–2024 vaccine (aOR 0.31, 95% CI 0.28–0.34). Updated-vaccine recipients numbered 6,336 (10% of cohort). Analyses used mixed-effects logistic regression adjusting for demographics, clinical risk, social vulnerability, and medications.

Key findings

  • Receipt of COVID-19 vaccination was associated with lower adjusted odds of COVID-19–related hospitalization compared with no vaccination; adjusted odds ratios were 0.59 (initial series), 0.29 (booster), and 0.31 (updated 2023–2024) versus unvaccinated.initial series aOR 0.59 (95% CI 0.56–0.63); booster aOR 0.29 (95% CI 0.27–0.31); updated aOR 0.31 (95% CI 0.28–0.34)
“We conducted a retrospective cohort study using National Clinical Cohort Collaborative (N3C) data”
2secondary dataEstimate the association between COVID-19 vaccination status and severe COVID-19 outcomes (mechanical ventilation/ECMO) and death in the same autoimmune rheumatic cohort.Retrospective cohort analysis (N3C) with mixed-effects logistic regressionExpand

In plain English

In a retrospective N3C cohort of adults with autoimmune rheumatic conditions and incident COVID-19 (Dec 2020–Aug 2024; n=60,980), the authors assessed associations between COVID-19 vaccination status (unvaccinated, initial series, booster, updated 2023–2024) and secondary severe outcomes — mechanical ventilation or ECMO, and death — using mixed-effects logistic regression adjusted for demographics, clinical risk, social vulnerability, and medications. The abstract states these associations were assessed but does not report effect estimates, confidence intervals, or event counts for the mechanical ventilation/ECMO or death models.

Key findings

  • The study assessed the association between COVID-19 vaccination status and need for mechanical ventilation or ECMO using adjusted mixed-effects logistic regression, but the abstract does not report effect estimates, confidence intervals, or event counts for this outcome.
  • The study assessed the association between COVID-19 vaccination status and death using adjusted mixed-effects logistic regression, but the abstract does not report effect estimates, confidence intervals, or event counts for mortality.
“We assessed the association between COVID‐19 vaccination status ... and ... mechanical ventilation or extracorporeal membrane oxygenation (ECMO), and death.”
What this piece can’t prove
  • Abstract does not present results (effect sizes, CIs, or event counts) for the mechanical ventilation/ECMO or death models.

2 further details could not be confirmed from the summary.

3secondary dataQuantify absolute risk reduction comparing initial-series-only vaccination vs booster/updated vaccination for COVID-19–related hospitalization in this cohort.Retrospective cohort subgroup contrast (initial-series-only vs booster/updated)Expand

In plain English

The study reports an absolute risk reduction of 5.6% for COVID-19–related hospitalization when comparing patients who received only the initial COVID‑19 vaccine series versus those who received a booster or an updated (2023–2024) vaccine, within an N3C retrospective cohort of adults with autoimmune rheumatic conditions.

Key findings

  • Among patients who had received only the initial vaccine series versus a booster/updated vaccine, the absolute risk reduction for COVID‑19–related hospitalization was 5.6% (reported in abstract).5.6% absolute risk reduction
“Among patients who had received only the initial vaccine series versus a booster/updated vaccine, the absolute risk reduction was 5.6%.”
What this piece can’t prove
  • Absolute risk reduction reported in abstract without accompanying uncertainty (CI) or subgroup event rates/denominators.
  • Unclear from abstract whether the absolute risk reduction was computed from adjusted model predictions or crude subgroup rates.
  • Retrospective observational design; potential for confounding by indication, differences in baseline risk, or other unmeasured factors between vaccination subgroups.
Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Open the paper in Tessa

Updated COVID ‐19 Vaccines and Health Outcomes in Patients With Autoimmune Rheumatic Conditions

Arthritis & Rheumatology · 2026

Source record (opens in a new tab)

Why this one

Near certain

NewsLink found the paper. Tessa is where you inspect it deeply.

Papers considered

The selected paper, plus nearby candidates.

Crossref, PubMed, Europe PMC · 16 candidate papers

Selected

Updated COVID ‐19 Vaccines and Health Outcomes in Patients With Autoimmune Rheumatic Conditions

Arthritis & Rheumatology · 2026 · Crossref

Source (opens in a new tab)
CandidateOpen access

COVID-19 Vaccination, Hospitalization Rates, and Mortality Differ Between People with Diagnosed Immune Mediated Inflammatory Disease and the General Population: A Population-Based Study.

Vaccines · 2025 · PubMed, Europe PMC

Tessa (opens in a new tab)Source (opens in a new tab)
Candidate

Self-Reported Delayed Adverse Events and Flare Following COVID-19 Vaccination Among Patients With Autoimmune Rheumatic Disease (AIRD) in Malaysia: Results From the COVAD-2 Study.

International Journal of Rheumatic Diseases · 2025 · PubMed

Tessa (opens in a new tab)Source (opens in a new tab)

And 10 more candidates considered.